Wegovy Safety: What to Expect, What to Watch For

Step 1: Understand what commonly happens in the first weeks

The body needs time to adjust to semaglutide. In the first few weeks (and again after each dose increase) the most frequently reported effects are nausea, vomiting, diarrhoea, constipation, indigestion and burping. Fatigue and headaches are also common in this early phase. None of this is unusual, and for the majority of people it settles as the body acclimates.

Eating smaller portions, avoiding fatty or very spicy meals, and staying well hydrated all tend to help. The full side-effect picture for Wegovy goes into more practical detail if you want a longer read before starting. The adjustment period is also part of why the dose is titrated gradually: beginning at a low level and climbing in stages gives your system the time it needs. That design is intentional, not arbitrary.

Injection-site reactions (mild redness, swelling or itching where the pen was used) are also reported by some people. Rotating sites between the abdomen, thigh and upper arm, and cleaning the area first, helps reduce this. The pen itself arrives by tracked DPD delivery in plain, unmarked packaging; inside is a pre-filled device with a covered needle that retracts automatically after use, which most people find less daunting than they expected.

Step 2: Know the warning signs that need urgent medical attention

A small number of serious effects require you to stop treatment and seek help promptly. The most important is acute pancreatitis. In January 2026 the MHRA issued a Drug Safety Update specifically flagging this risk for GLP-1 medicines: if you develop severe stomach pain that does not ease (particularly pain that spreads towards your back, with or without vomiting) you should seek emergency care rather than waiting to see if it resolves. This applies even if you have had no digestive problems up to that point.

Other situations that need prompt attention include signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing, rapid heartbeat), symptoms suggesting gallbladder problems (upper-right abdominal pain, especially after eating fatty food), and signs of significant dehydration if severe vomiting or diarrhoea prevents you from keeping fluids down. People with diabetes using other glucose-lowering medicines alongside Wegovy should also be aware of hypoglycaemia risk; a prescriber will discuss this at assessment.

You can read more about the semaglutide safety concerns that have been identified through clinical use and regulatory review if you want a fuller picture of what to watch for. You can also read more about the clinical safety profile of Wegovy as documented in its authorisation data. If in doubt at any point, contact a healthcare professional rather than waiting.

Step 3: Review contraindications and who should not use it

The safety of Wegovy in certain groups is either unknown or specifically unfavourable. It should not be used during pregnancy or while breastfeeding, and current guidance recommends stopping treatment and using effective contraception for a period before trying to conceive. A prescriber will discuss timing with you. Anyone under 18 is outside the licensed age range.

People with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia type 2 (MEN2), should not take semaglutide. A history of pancreatitis, or certain inflammatory bowel conditions, requires careful prescriber assessment before treatment is considered. These are not theoretical exclusions: they sit in the medicine's prescribing information and are checked as part of any proper clinical consultation.

The NHS semaglutide page lists the full set of conditions and medicines that your prescriber needs to know about before Wegovy is prescribed. Sharing an accurate medical history (including all medicines you take, whether prescription or over-the-counter) is genuinely the single most important safety step a patient can take. The question of whether Wegovy is safe for you personally is a clinical one, not a general one.

Step 4: What to do during treatment and how to report concerns

Once you are on treatment, ongoing monitoring matters. Weight, any emerging symptoms and how you are tolerating the current dose are all worth noting, particularly before dose increases. The MHRA's Yellow Card reporting tool lets patients report suspected side effects directly; for a medicine that is still under additional monitoring (Wegovy carries a Black Triangle designation), these real-world reports contribute to the evidence base and can prompt regulatory review if a pattern emerges.

If you have broader questions about how the long-term evidence on semaglutide is developing, our dedicated semaglutide safety guidance covers what regulators and clinical teams currently know, alongside the long-term safety data for semaglutide which covers what the clinical programme has and has not yet established. Treatment decisions over months and years are not a set-and-forget process; a good prescribing service reviews your case before every repeat, and at nume every repeat order is clinically re-reviewed by a GPhC-registered prescriber, not processed automatically. Start with a free consultation to discuss your suitability, your medical history and any safety questions with our prescribers directly.